X
[{"orgOrder":0,"company":"Vitaeris","sponsor":"CSL","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CSL Behring to Acquire Biotech Company Vitaeris","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"CANADA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Vitaeris"},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aurinia Presents Voclosporin Efficacy and Pharmacokinetic Data from Integrated Analysis of AURA-LV and AURORA Pivotal Trials","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"CANADA","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2020","url1":"","url2":"","graph1":"Peptide","graph2":"Aurinia Pharmaceuticals"},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aurinia Presents Integrated Time to Renal Response Data from the AURA-LV and AURORA Trials","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"CANADA","productType":"Peptide","productStatus":"New Molecular Entity","date":"November 2020","url1":"","url2":"","graph1":"Peptide","graph2":"Aurinia Pharmaceuticals"},{"orgOrder":0,"company":"Evolve Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evolve Biologics\u00ae Completes Phase III Adult and Pediatric Trials for Plasmacap\u2122 Ig (Intravenous Immunoglobulin)","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"CANADA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Evolve Biologics"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
Filters
Details:
Multicenter study of the efficacy, safety, tolerability, and pharmacokinetics of PlasmaCap IG in adults and children with primary immune deficiency disease met all primary and secondary endpoints.
Lead Product(s):
Human Immunoglobulin
Therapeutic Area: Immunology
Product Name: PlasmaCap IG
Highest Development Status: Phase III
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
February 09, 2021
Details:
Integrated analysis confirms addition of voclosporin to standard-of-care resulted in faster Renal Response compared to standard-of-care alone in lupus nephritis.
Lead Product(s):
Voclosporin
Therapeutic Area: Immunology
Product Name: ISA247
Highest Development Status: Phase III
Product Type: Peptide
Partner/Sponsor/Collaborator:
Otsuka Pharmaceutical
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
November 09, 2020
Details:
Integrated analysis confirms statistically superior efficacy and safety of voclosporin in combination with MMF and steroids over standard-of-care.
Lead Product(s):
Voclosporin ,Mycophenolate Mofetil
Therapeutic Area: Immunology
Product Name: ISA247
Highest Development Status: Phase III
Product Type: Peptide
Partner/Sponsor/Collaborator:
Otsuka Pharmaceutical
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
October 22, 2020
Details:
With this acquisition, clazakizumab joins CSL842 and CSL964 as part of CSL Behring’s portfolio of products in late-stage development to address significant unmet needs in the transplant community.
Lead Product(s):
Clazakizumab
Therapeutic Area: Immunology
Product Name: Undisclosed
Highest Development Status: Phase III
Product Type: Large molecule
Partner/Sponsor/Collaborator:
CSL
Deal Size: Undisclosed
Upfront Cash: Undisclosed
Deal Type: Acquisition
June 08, 2020